. . . Shops Leiner, Sterigenics Deals

UBS is also launching deals this week for Leiner Health Products and Sterigenics International.

  • 30 Apr 2004
Email a colleague
Request a PDF

UBS is also launching deals this week for Leiner Health Products and Sterigenics International. The Leiner facility, led by UBS, Morgan Stanley and Credit Suisse First Boston, is made up of a five-year, $50 million revolver and seven-year, $240 million term loan. The Sterigenics deal comprises a $35 million revolver, $170.5 million term loan and $35 million second-lien term loan. Price talk on the first- and second-lien term loans is LIBOR plus 3% and 6 1/4%, respectively. Ballpark pricing on the revolver was not available. The Leiner credit backs a $650 million recapitalization of the vitamin maker by North Castle Partners and Golden Gate Capital. The Sterigenics deal backs PPM Ventures' and PPM America Capital Partners' acquisition of the sterilization and ionization business of Ion Beam Applications. A PPM official declined comment.

  • 30 Apr 2004

GlobalCapital European securitization league table

Rank Lead Manager/Arranger Total Volume $m No. of Deals Share % by Volume
1 Bank of America Merrill Lynch (BAML) 6,415 22 12.84
2 Citi 5,781 17 11.57
3 BNP Paribas 3,530 14 7.06
4 Credit Suisse 2,783 8 5.57
5 Rabobank 2,633 4 5.27

Bookrunners of Global Structured Finance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 99,251.11 279 13.15%
2 Bank of America Merrill Lynch 90,895.27 265 12.04%
3 Wells Fargo Securities 72,661.39 222 9.63%
4 JPMorgan 52,367.24 169 6.94%
5 Credit Suisse 41,885.89 127 5.55%